4505 EMPEROR BOULEVARD, DURHAM, NC
Financial Results, Reg. FD
Amended material disclosure
Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility
Stockholders Approve Amendment to BioCryst Stock Incentive Plan
Reports First Quarter 2026 Financial Results and Provides Business Update
Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema
Annual Report to Security Holders
Reports Full Year 2025 Financial Results and Provides Business Update
Q2
Q1
FY 2024
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
S-4/A
Prospectus Filed Pursuant to Rule 425
S-4
Definitive Proxy Statement
Additional Proxy Materials
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload
SEC Staff Correspondence